Benralizumab's anti-eosinophil efficacy may be decreased by impaired NK cell activity
Eur Respir J
.
2022 Apr 7;59(4):2102210.
doi: 10.1183/13993003.02210-2021.
Print 2022 Apr.
Authors
Sophie M Poznanski
1
,
Ana Portillo
1
,
Manali Mukherjee
2
,
Anurag Bhalla
2
,
Kiho Son
2
,
Ali A Ashkar
1
,
Nader Khalidi
3
,
Parameswaran Nair
4
Affiliations
1
Division of Clinical Immunology and Allergy, McMaster University and St Joseph's Healthcare, Hamilton, ON, Canada.
2
Division of Respirology, McMaster University and St Joseph's Healthcare, Hamilton, ON, Canada.
3
Division of Rheumatology, McMaster University and St Joseph's Healthcare, Hamilton, ON, Canada.
4
Division of Respirology, McMaster University and St Joseph's Healthcare, Hamilton, ON, Canada parames@mcmaster.ca.
PMID:
34887323
DOI:
10.1183/13993003.02210-2021
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized* / therapeutic use
Eosinophils*
Humans
Killer Cells, Natural
Leukocyte Count
Substances
Antibodies, Monoclonal, Humanized
benralizumab